Unfortunately an early study suggests that GLP-1s do not, so far, reduce medical spending, with little offset in other spending being observed or projected. Given this is a highly effective treatment that reduces diabetes and cardiovascular risks, that is a weird result, and suggests something is broken in the medical system.
Isn’t that just the pricing mechanism working as intended? GLP-1s are not cheap. You spend money on a drug instead of on the medical problems that the drug reduces your risk for. You get to enjoy whatever non-monetizable value ensues from taking the drug … but all the monetizable value is captured by the company that makes the drug (and the rest of the medical system that delivers it to you).
Isn’t that just the pricing mechanism working as intended? GLP-1s are not cheap. You spend money on a drug instead of on the medical problems that the drug reduces your risk for. You get to enjoy whatever non-monetizable value ensues from taking the drug … but all the monetizable value is captured by the company that makes the drug (and the rest of the medical system that delivers it to you).